PDCD1 and neoplasm: However, though predictive biomarkers such as PD-L1 expression and tumor mutation burden could identify the patient subpopulation that responded to PD-1/PD-L1 mAbs, only 20% of NSCLC patients benefit from monotherapy [2, 3].